Glucagon’s Ketogenic Effect: A Technical Pros and Cons Analysis
Published: July 15, 2026 17:37
Author: Julia Herrera
Abstract: Glucagon’s ketogenic effect, driven by hepatic glycogenolysis and fatty acid oxidation, offers therapeutic potential in metabolic disorders but poses risks of hyperglycemia and nausea. Current peptide products (e.g., dasiglucagon) show superior stability versus native glucagon, yet face high production costs and cold-chain logistics challenges. Market trends favor dual-agonist peptides (GLP-1/glucagon) for obesity, with Novo Nordisk and Eli Lilly leading. Key technical parameters include purity (>98%) and bioassay potency. Regulatory compliance (FDA/EMA) and factory GMP certification are critical for quality assurance. Selection criteria emphasize stability, delivery system, and clinical trial data.